Albert Cha is Director at KalVista Pharmaceuticals, Inc. (KALV). They have made 12 open-market trades across 7 companies since 2008, most recently 2023-09-11.
CIK 0001397906
10 open-market purchases totalling $53.0M since 2015, against 2 sales. Across 9 scored buys the stock is down 15.7% at ninety days, and 14.9 points behind the S&P over the same stretch.
9 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 44% | 44% | 22% |
| Avg Move | -4.6% | +0.2% | -15.7% |
| Alpha | -1.9% | +0.5% | -14.9% |
| Scored | 9 | 9 | 9 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KALV | SELL | 2023-09-11 | 2023-09-13 | $10.50 | $189K | -4.9% | -9.8% | -3.1% |
| KALV | BUY | 2020-10-30 | 2020-11-03 | $17.24 | $4.0M | +2.8% | +1.3% | -16.9% |
| KALV | BUY | 2019-07-26 | 2019-07-30 | $16.99 | $1.9M | -7.4% | -7.7% | -29.8% |
| KALV | BUY | 2019-07-17 | 2019-07-19 | $17.80 | $2.2M | -8.2% | -8.3% | -33.3% |
| KALV | BUY | 2018-09-10 | 2018-09-12 | $17.00 | $18.0M | +28.5% | +14.0% | +40.8% |
| MNLO | BUY | 2018-01-25 | 2018-01-29 | $17.00 | $5.0M | +10.1% | +3.9% | -75.8% |
| BHVN | BUY | 2017-05-09 | 2017-05-09 | $17.00 | $8.0M | +10.5% | +10.3% | +20.3% |
| ACRS | BUY | 2015-10-13 | 2015-10-13 | $11.00 | $5.0M | -24.9% | -1.7% | -27.6% |
| ACRS | BUY | 2015-10-07 | 2015-10-09 | $11.00 | $147K | -24.9% | -1.7% | -10.7% |
| DNAI | BUY | 2015-07-21 | 2015-07-21 | $17.00 | $3.7M | -27.9% | -8.5% | -8.5% |
| CBYL | BUY | 2015-04-14 | 2015-04-27 | $5.00 | $5.1M | N/A | N/A | N/A |
| BIOD | SELL | 2008-02-12 | 2008-02-14 | $15.50 | $2.0M | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| CBYL |
| 4,197,198 |
| — |
| BFRM | 61,394 | — |
| Total | $45.0M |
Shares reported on the most recent Form 4, priced at the 2023-09-13 close. 3 holdings could not be priced and are excluded from the total.